Stifel Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $34
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.
Stifel analyst Paul Matteis initiates coverage on City Therapeutics (NASDAQ:CTY) with a Buy rating and announces Price Target of $34.